January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe 

January 29, 2024 — The Society of Thoracic Surgeons has released late-breaking research scheduled for presentation at the 2024 Annual Meeting taking place January 27 - 29 in San Antonio.

January 29, 2024 — Jennifer C. Romano, MD, a congenital heart surgeon at Congenital Heart Center/C. S. Mott Children's Hospital, and the Herbert Sloan Collegiate Professor of Cardiac Surgery at the University of Michigan Medical School, was elected president of The Society of Thoracic Surgeons at STS 2024 during the Society’s Business Meeting. The selection makes Dr.

DAIC's exclusive, specialized cardiology product comparison charts help with your purchasing decisions

Did you know that Diagnostic and Interventional Cardiology (DAIC) maintains more than 40 comparison charts of product specifications from various vendors, offering a side-by-side, apples-to-apples comparison when making purchasing decisions? These charts can save hours of research, and offer links back to the websites of each vendor for additional information. The charts were created by DAIC by sending out a questionnaire to each of the vendors listed. 

January 25, 2024 — New research confirms what public health leaders have been fearing: the significant uptick in the cardiovascular disease (CVD) death rate that began in 2020 has continued.

January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti-inflammatory cardiovascular treatment (

January 25, 2024 — The American College of Cardiology’s Cardiovascular Summit (CV Summit) will take place on February 1-3 in Washington, DC.

The Smidt Heart Institute recently received CAROL Act funding to study the connection between ventricular arrhythmias-abnormal heartbeats that start in the heart’s two lower chambers-and an elevated risk of sudden cardiac death in patients with mitral valve disease

You may not know 
While reinforcing the importance of treating all known risk factors that contribute to atherosclerotic cardiovascular disease, ASCVD, physicians also need to recognize and treat systemic inflammation in CV disease, according to this guest column author who addresses the importance of identifying and reducing residual inflammatory risk.

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now